Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Market Value Is The Isocitrate Dehydrogenase (IDH) Inhibitors Industry Expected To Reach By 2029, Starting From 2025 Levels?
The market for isocitrate dehydrogenase (idh) inhibitors has experienced exponential expansion in recent years. It is projected to grow from $1.94 billion in 2024 to $2.46 billion in 2025, at a compound annual growth rate (CAGR) of 27.0%. The expansion observed in prior periods can be attributed to an increased incidence of hematologic cancers, enhanced genetic profiling in oncology, the clinical success of targeted therapies, various precision medicine initiatives, and a rise in healthcare spending specifically within oncology.
The market size for isocitrate dehydrogenase (idh) inhibitors is projected to experience significant expansion over the coming years. It is forecast to reach $6.34 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 26.7%. This projected growth during the forecast period is attributable to supportive reimbursement policies, an increasing incidence of blood cancers, rising awareness among oncologists, the growing adoption of precision medicine, and an increase in healthcare infrastructure and oncology centers. Prominent trends for the forecast period include advancements in genomic and molecular diagnostics, collaborations and licensing deals, progress in drug delivery technologies, improvements in diagnostic technologies, and the development of combination therapies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Isocitrate Dehydrogenase (IDH) Inhibitors Industry?
The anticipated rise in acute myeloid leukemia cases is poised to drive the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is a rapidly progressing blood and bone marrow cancer characterized by the swift production of abnormal white blood cells that interfere with typical blood cell formation. The increasing incidence of acute myeloid leukemia is attributed to the growing aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors play a crucial role in treating acute myeloid leukemia by blocking mutant IDH enzymes, which in turn helps restore normal blood cell development and slow the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, stated that from 2022 to 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). This anticipated increase in acute myeloid leukemia frequency is therefore expected to significantly propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
What Are The Primary Types Of Segments Analyzed In The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The isocitrate dehydrogenase (IDH) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
Which Trends Are Impacting The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Companies actively involved in the isocitrate dehydrogenase (IDH) inhibitors market are concentrating on acquiring regulatory approvals. This strategy aims to broaden the clinical application of their treatments, accelerate their market entry, and establish a competitive edge in IDH-mutant cancer therapy. Regulatory approvals are formal authorizations granted by health authorities, allowing a drug to be commercialized and utilized after its safety and effectiveness have been confirmed. As an illustration, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, secured FDA approval for VORANIGO (vorasidenib) tablets. This approval positioned it as the inaugural targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma, which possess IDH1 or IDH2 mutations. This oral treatment demonstrated a substantial improvement in progression-free survival, as evidenced in the Phase 3 INDIGO trial, where the median progression-free survival for patients was 27.7 months, contrasting with 11.1 months for the placebo group. VORANIGO presents a convenient and generally well-tolerated option with manageable adverse effects, signifying a crucial progression for a patient population with restricted prior treatment alternatives.
Who Are The Top Performing Companies In The Isocitrate Dehydrogenase (IDH) Inhibitors Market In Recent Years?
Major companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Download The Full Report For Exclusive Market Findings:
What Are The Regional Market Dynamics Impacting The Isocitrate Dehydrogenase (IDH) Inhibitors Industry?
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/customise?id=24577&type=smp
Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2025, By The Business Research Company
Histone Deacetylase Inhibitors Global Market Report 2025
Metabolic Disorders Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Proton Pump Inhibitors Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model